Chardan Capital assumed coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research note published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the company. 92 Resources reiterated a reiterates rating on […]